Uptake of screening and prevention in women at very high risk of breast cancer
- PMID: 11567707
- DOI: 10.1016/S0140-6736(01)06039-1
Uptake of screening and prevention in women at very high risk of breast cancer
Abstract
Management of women at high lifetime risk of familial breast cancer is hampered because of limited data concerning the appropriateness of treatment options. Over the past 8 years women at very high (>40%) lifetime risk of breast cancer have had the option of entering two chemoprevention treatment trials, a magnetic resonance imaging (MRI) breast screening study, or a risk-reducing mastectomy (RRM) study. Only 10% of eligible women have entered one of the chemotherapy trials with a similar proportion opting for RRM (>50% in mutation carriers) compared with 60% opting for MRI screening. Future chemotherapy trials will have to be designed to address this poor recruitment.
Comment in
-
Recruitment of women into trials.Lancet. 2002 Jan 12;359(9301):164. doi: 10.1016/s0140-6736(02)07341-5. Lancet. 2002. PMID: 11809281 No abstract available.
-
Recruitment of women into trials.Lancet. 2002 Jan 12;359(9301):165. doi: 10.1016/S0140-6736(02)07343-9. Lancet. 2002. PMID: 11809282 No abstract available.
-
Recruitment of women into trials.Lancet. 2002 Jan 12;359(9301):165-6. doi: 10.1016/S0140-6736(02)07344-0. Lancet. 2002. PMID: 11809283 No abstract available.
-
Recruitment of women into trials.Lancet. 2002 Jan 12;359(9301):164-5. doi: 10.1016/S0140-6736(02)07342-7. Lancet. 2002. PMID: 11809284 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
